Group 1: Market Overview - The ophthalmic product market is expanding, with a significant consumer attribute, and sales are less affected by centralized procurement [1] - The company has acquired 13 varieties of eye drops, including Jin Zhen eye drops and others, which are actively promoted [1] Group 2: Research and Development - The company is developing innovative drugs based on antibody fusion proteins, with promising animal trial results [1] - There is ongoing development of complex formulations using the company's permeation pump technology [1] - The company is also focusing on traditional Chinese medicine and has initiated several projects in this area [1] Group 3: Shareholder Actions - One supervisor disclosed a reduction of over 300,000 shares, with a plan not exceeding 75,900 shares, indicating minimal impact [2] - Institutional shareholders hold a total of 3.48 million shares, accounting for 5.01% of the company's total share capital [2] Group 4: Product Strategy - The company plans to innovate in the field of controlled substances, with several products in the registration phase [2] - The Yiqi Hewei capsule has seen rapid growth due to its status as a unique essential drug, with significant potential for further sales growth [2] Group 5: Sales and Marketing - The sales team is structured into clinical and OTC channels, with a specialized team for ophthalmic products [4] - The company does not currently have major products participating in centralized procurement [4] Group 6: Future Outlook - The company anticipates maintaining good sales growth for Felodipine sustained-release tablets, which are not yet subject to centralized procurement [3] - The first batch of Nifedipine controlled-release tablets is ready for market, with centralized procurement expected to occur in March-April [3]

证券代码：003020 证券简称：立方制药 公告编号：2022-056 合肥立方制药股份有限公司 关于参加安徽辖区上市公司 2022 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，合肥立方制药股份有限公司（以下简称 "公司"）将参加由安徽证监局指导、安徽上市公司协会与深圳市全景网络有限 公司联合举办的"2022 年安徽辖区上市公司投资者集体接待日活动"，现将相 关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站（ http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP，参与本 次互动交流，活动时间为2022年9月7日（周三）16：00-17：30。届时公司高管将 在线就公司2022年上半年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告。 合肥立方制药股份有限公司 董事会 2022年9月2日 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,229,226,368.22, representing a 14.47% increase compared to ¥1,073,808,952.34 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was ¥98,169,945.12, up 17.45% from ¥83,584,376.44 in the previous year[21]. - Basic earnings per share rose to ¥0.82, an increase of 18.84% from ¥0.69 in the previous year[21]. - The company reported a net profit excluding non-recurring gains and losses of ¥90,950,026.61, which is an 18.22% increase from ¥76,935,297.65 in the previous year[21]. - The company's total revenue for the reporting period reached CNY 1,229,226,368.22, representing a year-on-year increase of 14.47% compared to CNY 1,073,808,952.34[44]. - The company reported a significant increase in asset impairment losses by 258.75% due to increased inventory write-downs[48]. - The comprehensive income for the first half of 2022 amounted to CNY 98,169,945.12, compared to CNY 83,584,376.44 in the same period of 2021, indicating an increase of about 17.5%[165][166]. Cash Flow and Investments - The net cash flow from operating activities increased significantly by 219.46%, reaching ¥131,734,187.26 compared to ¥41,237,151.20 in the same period last year[21]. - The company reported a net cash flow from operating activities of CNY 131,734,187.26, a substantial increase of 219.46% compared to CNY 41,237,151.20 from the previous year[44]. - The net cash flow from investment activities was negative at CNY -485,387,231.76, an improvement from CNY -579,280,601.86 in the previous year, indicating a reduction in cash outflow by 16.2%[158]. - The company’s cash inflow from operating activities was primarily driven by sales revenue of CNY 1,109,303,943.09, which increased from CNY 925,914,543.07 in the previous year, marking a growth of 19.8%[157]. - The company received CNY 180,000,000.00 from other investment-related cash inflows, down from CNY 600,000,000.00 in the previous year[158]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,962,220,825.85, reflecting a 17.19% increase from ¥1,674,444,924.99 at the end of the previous year[21]. - Total liabilities increased to ¥624,988,109.98 as of June 30, 2022, compared to ¥370,534,154.24 at the beginning of the year, reflecting a growth of about 68.5%[146]. - Total current assets increased to ¥1,422,629,521.96 as of June 30, 2022, from ¥1,219,647,719.01 at the beginning of the year, representing a growth of approximately 16.6%[145]. - Cash and cash equivalents decreased significantly to ¥272,483,992.74 from ¥654,253,951.34, a decline of about 58.4%[144]. - Trade receivables increased by 30.24% to ¥368,127,326.07, primarily due to unexpired customer credit receivables[47]. Research and Development - The company focuses on high-end formulation research and production, with key products including sustained-release tablets for hypertension and benign prostatic hyperplasia[28]. - The company has a strong emphasis on R&D, with a dedicated drug research institute and collaborations with universities and research institutions[33]. - The company is actively engaged in the research and development of controlled substances, with ongoing studies for oxycodone sustained-release tablets[35]. - Research and development expenses for the first half of 2022 amounted to CNY 31,181,734.35, up from CNY 29,092,255.24 in the previous year[152]. - The company has developed a permeation pump controlled-release technology platform, which has been recognized with the first prize of the Anhui Provincial Science and Technology Award in 2018[34]. Market and Product Development - The pharmaceutical manufacturing segment generated CNY 471,042,416.81, accounting for 38.32% of total revenue, with a growth of 10.05% from the previous year[45]. - The pharmaceutical wholesale and distribution segment saw revenue of CNY 695,830,960.04, which is 56.61% of total revenue, reflecting a 16.69% increase year-on-year[45]. - The company has a robust pipeline of products, including traditional Chinese medicine that has been included in the national essential drug list[29]. - The company has signed an agreement to acquire the ownership of 13 eye drop products for CNY 38 million, marking its entry into the ophthalmology field[36]. - The company has developed two EDB single-chain antibody fusion protein patents, demonstrating significant advantages in tumor targeting and long-lasting effects[37]. Governance and Compliance - The company’s governance structure includes a board of directors and several specialized committees, ensuring compliance with national laws and regulations[179]. - The company has implemented safety management systems to mitigate risks associated with hazardous materials in production processes[75]. - The company has established measures to ensure compliance with environmental standards, including regular maintenance of pollution control facilities[88]. - The company has complied with all environmental impact assessment requirements for its projects and received necessary government approvals[90]. - The company has not engaged in any significant litigation or arbitration matters during the reporting period[104]. Shareholder and Capital Structure - The total number of shares increased from 92,640,000 to 120,432,000 due to a capital reserve conversion, with a ratio of 10 shares to 3 new shares issued[125]. - The largest shareholder, Ji Junqiu, holds 27.58% of the shares, totaling 33,213,180 shares, with an increase of 7,664,580 shares during the reporting period[130]. - The total equity attributable to the parent company at the end of the first half of 2022 was CNY 1,337,232,715.87, an increase from CNY 1,303,910,770.75 at the end of 2021, representing a growth of approximately 2.54%[165]. - The company has implemented a capital reserve conversion plan approved at the 2021 annual general meeting, effective from May 23, 2022[125]. - The company reported a total of 44,564,520 shares held by directors and senior management at the end of the reporting period, with an increase of 10,284,120 shares during the period[133].

Financial Performance - The company's revenue for Q1 2022 was ¥628,617,238.94, representing a 14.48% increase compared to ¥549,093,775.22 in the same period last year[3] - Net profit attributable to shareholders was ¥47,126,894.93, up 13.04% from ¥41,691,278.46 year-on-year[3] - Total operating revenue for Q1 2022 was CNY 628,617,238.94, an increase of 14.5% compared to CNY 549,093,775.22 in the same period last year[23] - Net profit for Q1 2022 reached CNY 47,126,894.93, representing a 13.0% increase from CNY 41,691,278.46 in Q1 2021[24] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.51, compared to CNY 0.45 in the same period last year[25] Cash Flow and Liquidity - The net cash flow from operating activities increased by 90.76% to ¥14,015,957.65, compared to ¥7,347,550.03 in Q1 2021[3] - The net cash flow from financing activities was -3,094,585.68, compared to -4,599,124.38 in the previous period, indicating an improvement of approximately 32.7%[29] - The net increase in cash and cash equivalents for the period was -480,845,312.40, compared to -592,230,291.32 in the previous period, reflecting a reduction of about 18.8%[29] - The company's cash and cash equivalents decreased to RMB 180,099,316.29 from RMB 654,253,951.34, representing a decline of about 72.5%[18] - The company’s cash and cash equivalents decreased by approximately 83.6% from the beginning to the end of the period[29] Assets and Liabilities - Total assets at the end of Q1 2022 reached ¥1,899,968,983.75, a 13.47% increase from ¥1,674,444,924.99 at the end of the previous year[3] - The total current liabilities increased to RMB 508,970,681.33 from RMB 328,053,931.54, which is an increase of about 55%[20] - The total liabilities at the end of Q1 2022 were CNY 548,931,318.07, up from CNY 370,534,154.24 at the beginning of the year[21] - The total equity attributable to shareholders of the parent company was CNY 1,351,037,665.68, an increase from CNY 1,303,910,770.75 at the start of the year[21] - The company reported a total non-current asset value of RMB 474,764,515.58, up from RMB 454,797,205.98 at the beginning of the year, reflecting an increase of approximately 4.5%[19] Operational Metrics - Accounts receivable increased by 46.97% to ¥415,430,214.90, primarily due to new sales and unexpired credit terms with downstream customers[8] - Inventory levels rose by 44.89% to ¥273,628,907.68, attributed to normal stockpiling in the pharmaceutical business[8] - Research and development expenses for Q1 2022 totaled CNY 13,199,412.15, slightly up from CNY 12,404,825.37 in Q1 2021[24] - Sales expenses increased to CNY 162,523,573.63 in Q1 2022, compared to CNY 143,103,211.68 in the previous year[24] Government Support and Equity - The company received government subsidies amounting to ¥2,610,896.60, which is a 328.92% increase compared to ¥608,718.15 in Q1 2021[10] - The company plans to transfer 4.9383% equity in Minoway for RMB 32,098,800, pending completion of regulatory filings[16] - The company holds a 12.3457% stake in Nanjing Minoway Pharmaceutical Technology Co., Ltd. as of January 21, 2022[15] Reporting and Audit - The first quarter report was not audited, which may affect the reliability of the financial data presented[30] - The report was issued by the board of directors on April 29, 2022, indicating the timeliness of the financial disclosure[31]

Financial Performance - The company's operating revenue for 2021 was ¥2,273,254,476.86, representing a 20.01% increase compared to ¥1,894,291,431.49 in 2020[21]. - The net profit attributable to shareholders for 2021 was ¥172,227,170.61, an increase of 27.47% from ¥135,116,122.69 in 2020[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥151,766,711.42, up 28.75% from ¥117,875,523.70 in 2020[21]. - The company's total assets at the end of 2021 were ¥1,674,444,924.99, a 9.01% increase from ¥1,536,019,607.62 at the end of 2020[21]. - The net cash flow from operating activities for 2021 was ¥158,702,671.45, a decrease of 7.99% compared to ¥172,489,276.44 in 2020[21]. - The company reported a basic earnings per share of ¥1.86 for 2021, down 4.12% from ¥1.94 in 2020[21]. - The company achieved total operating revenue of ¥2,273,254,476.86, a year-on-year increase of 20.01%[49]. - Net profit attributable to shareholders was ¥172,227,170.61, representing a growth of 27.47% compared to the previous year[49]. - The company achieved a total revenue of CNY 2.27 billion in 2021, representing a growth of 20.01% compared to 2020[60]. - The net profit for 2021 was CNY 172 million, an increase of approximately 27.47% year-on-year[60]. Research and Development - The company plans to strengthen innovation and invest in R&D for innovative drugs and high-end formulations to meet unmet clinical needs[33]. - The company employs various R&D models, including independent research, technology transfer, and collaborative development, focusing on areas like antibody drugs and ophthalmic medications[44]. - The company invested CNY 65.86 million in R&D in 2021, a year-on-year increase of 52.06%[61]. - The company's total R&D investment reached ¥72,537,070.50 in 2021, a 52.58% increase from ¥47,541,688.49 in 2020, representing 3.19% of total revenue[76]. - The company has established a drug research institute focusing on new drug and technology development, supported by a team of experts and collaborations with academic institutions[51]. - The company has obtained two patents for EDB single-chain antibody fusion proteins, advancing into innovative drug development with promising tumor-targeting characteristics[54]. - The company has several new product developments in progress, with multiple projects having completed pilot studies and awaiting production licenses[75]. Market Strategy and Expansion - The company aims to expand into consumer-oriented medical products to mitigate the impact of pharmaceutical policies on sales[33]. - The company has established over 60 retail chain pharmacies in Hefei and surrounding areas, enhancing its pharmaceutical retail business[43]. - The company intends to expand its online business and optimize logistics to reduce costs and improve delivery efficiency, aiming to become a regional leader in the pharmaceutical commercial sector[105]. - The company plans to utilize national procurement negotiations to expand its market presence and optimize operational efficiency in wholesale distribution[110]. - The company aims to enhance its pharmaceutical industrial capabilities by leveraging its osmotic pump controlled-release technology platform, focusing on high-end formulations to improve market competitiveness[101]. Corporate Governance - The company has established a comprehensive corporate governance structure and updated its internal control systems to protect shareholder rights[188]. - The company has a clear governance structure with independent directors overseeing operations, ensuring compliance and accountability[151]. - The company operates an independent financial accounting department, with no shared bank accounts with the controlling shareholder, ensuring autonomous financial decision-making[137]. - The company has a commitment to improving corporate governance and compliance with relevant laws and regulations to enhance operational transparency[124]. - The company has established a complete and independent supply, research and development, production, and sales system, with no reliance on the controlling shareholder for business operations[139]. Environmental Compliance - The company reported a total wastewater discharge of 1.742 tons for COD and 0.104 tons for ammonia nitrogen, with no exceedances of discharge standards[182]. - The company achieved a reduction of organic waste gas emissions by 134.08 kg/a through upgrades to its waste gas collection and treatment facilities[186]. - The company has implemented a clean production audit to promote energy conservation and emission reduction in its production processes[183]. - The company has established communication channels with investors, including online performance briefings and investor reception days, to enhance transparency[189]. - The company has complied with environmental impact assessment requirements for all construction projects and has received necessary government approvals[184]. Risk Management - The company has not identified any significant adverse risk factors affecting its operational and financial status[5]. - The company faces risks related to industry policies, including increased regulatory scrutiny and potential price reductions for certain drugs due to national procurement policies[113]. - The company is at risk of talent shortages and the loss of core technical personnel, which could impact its operational capabilities[114]. - New product development poses risks due to long R&D cycles and potential delays caused by technical difficulties or market factors[118]. - The company has established a comprehensive safety management system to mitigate risks associated with hazardous materials used in production[116]. Shareholder Information - The company reported a profit distribution plan of 7.00 RMB per 10 shares (including tax) and a capital reserve increase of 3 shares for every 10 shares held[5]. - The total cash dividend for the reporting period was RMB 64,848,000, which is fully compliant with the company's profit distribution policy[169]. - The company has a commitment to limit share transfers to no more than 25% of total shares held during the first year after the lock-up period ends[199]. - The company has confirmed that it will not engage in any competitive business activities that may conflict with its interests[200]. - The company has successfully fulfilled its commitments regarding share lock-up and transfer restrictions as of December 2020[199].

Financial Performance - The company's revenue for Q3 2021 reached ¥591,088,785.10, representing a year-on-year increase of 22.09%[3] - Net profit attributable to shareholders was ¥41,758,248.46, up 24.22% compared to the same period last year[3] - The net profit excluding non-recurring gains and losses was ¥37,487,510.07, reflecting a 22.92% increase year-on-year[3] - Total operating revenue for the current period reached ¥1,664,897,737.44, an increase of 21.0% compared to ¥1,376,200,536.00 in the previous period[19] - Net profit for the current period was ¥125,342,624.90, representing a 25.8% increase from ¥99,662,537.09 in the same period last year[21] - Total comprehensive income for the current period was ¥125,342,624.90, compared to ¥99,662,537.09 in the previous period[21] - Basic and diluted earnings per share were both ¥1.3530, slightly down from ¥1.4344 in the previous period[21] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥1,770,186,835.15, a 15.25% increase from the end of the previous year[3] - As of September 30, 2021, total assets amounted to CNY 1,770,186,835.15, an increase from CNY 1,536,019,607.62 at the end of 2020, representing a growth of approximately 15.2%[16] - The total liabilities rose to CNY 517,171,079.22 from CNY 362,026,476.59, marking an increase of about 43.0%[17] - Total liabilities increased from 362,026,476.59 to 382,768,647.30, marking a rise of approximately 5.9%[28] - Current liabilities totaled 342,348,403.07, unchanged from the previous period[28] Cash Flow and Investments - The company's cash flow from operating activities showed a net decrease of 24.64% year-to-date, totaling ¥116,367,931.67[3] - Cash flow from operating activities generated a net amount of ¥116,367,931.67, down 24.7% from ¥154,412,593.92 in the prior period[24] - The company experienced a net cash outflow from investing activities of ¥564,305,404.62, compared to a smaller outflow of ¥33,813,540.75 in the prior period[24] - The net increase in cash and cash equivalents was -¥507,697,451.75, a decrease of 1073.96% due to increased investments in structured deposits and long-term assets[9] - The company reported a significant cash inflow of ¥1,075,000,000.00 from other investment activities during the current period[24] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 66.04%, reaching ¥390,296,492.65, due to new sales and extended credit terms[7] - Accounts receivable increased significantly to CNY 390,296,492.65 from CNY 235,059,021.75, reflecting a growth of approximately 66.1%[15] - The company’s inventory increased to CNY 217,968,090.38 from CNY 193,799,902.99, representing a rise of approximately 12.4%[15] - The company’s inventory was reported at 193,799,902.99, maintaining operational efficiency[26] Corporate Governance and Strategic Initiatives - The company appointed a new non-independent director and vice general manager, Wang Qing, to enhance corporate governance[13] - The company made a strategic investment of ¥20,000,000.00 in Nanjing Mainowei Pharmaceutical Technology Co., Ltd[9] - The company received approval for the raw material drug methylphenidate hydrochloride and obtained a drug registration certificate for sustained-release tramadol tablets, enhancing its product pipeline[13] - The company reported no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[13] Research and Development - Research and development expenses increased to ¥42,897,403.88, up 27.2% from ¥33,720,047.12 in the previous period[20] Equity and Ownership - The company’s total equity attributable to shareholders increased to CNY 1,253,015,755.93 from CNY 1,173,993,131.03, reflecting a growth of about 6.8%[17] - Owner's equity remained constant at 1,173,993,131.03, indicating no change in shareholder equity[28]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,073,808,952.34, representing a 20.38% increase compared to CNY 892,039,676.92 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 83,584,376.44, up 26.55% from CNY 66,046,247.20 year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 76,935,297.65, an increase of 34.38% compared to CNY 57,251,929.08 in the previous year[20]. - The basic earnings per share decreased by 5.26% to CNY 0.90 from CNY 0.95 in the same period last year[20]. - The weighted average return on net assets was 6.96%, down 3.80% from 10.76% in the previous year[20]. - The company's revenue for the reporting period reached ¥1,073,808,952.34, representing a year-on-year increase of 20.38% compared to ¥892,039,676.92 in the same period last year, primarily driven by increased sales of pharmaceutical industrial products[49]. - The cost of sales was ¥639,216,732.86, up 5.28% from ¥607,185,931.87, indicating effective cost management despite rising sales[49]. - Research and development expenses surged by 94.32% to ¥34,541,544.59, up from ¥17,776,007.48, reflecting the company's commitment to enhancing clinical trial investments and R&D equipment[49]. - The company reported a total comprehensive income for the first half of 2021 was ¥83,584,376.44, compared to ¥66,046,247.20 in the first half of 2020[145]. Cash Flow and Investments - The net cash flow from operating activities decreased by 58.14% to CNY 41,237,151.20 from CNY 98,517,952.96 in the same period last year[20]. - The net cash flow from investing activities plummeted by 2,565.58% to -¥579,280,601.86, compared to -¥21,731,878.28, primarily due to investments in structured deposits and joint ventures[49]. - The company reported a net decrease in cash and cash equivalents of -¥582,085,294.76, a drastic decline of 3,879.06% from ¥15,402,917.54, largely attributed to structured deposits and dividend payments[49]. - The cash and cash equivalents at the end of the reporting period were ¥174,330,675.85, a decrease of 39.11% from ¥766,585,820.69, primarily due to investments in structured deposits and long-term assets[57]. - The company reported a significant cash outflow from investing activities, totaling ¥579,280,601.86, compared to an outflow of ¥21,731,878.28 in the same period last year[150]. - The cash outflow for purchasing fixed assets and other long-term assets was ¥73,959,370.94, a notable increase from ¥14,469,738.85 in the previous year, indicating aggressive asset acquisition[153]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,613,792,954.86, a 5.06% increase from CNY 1,536,019,607.62 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 3.17% to CNY 1,211,257,507.47 from CNY 1,173,993,131.03 at the end of the previous year[20]. - The company's total equity reached ¥1,071,134,824.07 as of June 30, 2021, compared to ¥1,039,920,682.68 at the end of 2020, showing an increase of 3.0%[141]. - Total liabilities reached ¥402,535,447.39, up from ¥362,026,476.59, reflecting an increase of about 11.1%[136]. - The company's accounts receivable increased to ¥315,605,561.32, representing 19.56% of total assets, up from 15.30% in the previous year, indicating a growing customer base[57]. Research and Development - The company has established a controlled-release technology platform, enhancing its product development capabilities, with key products including Felodipine sustained-release tablets and Doxazosin mesylate sustained-release tablets[29]. - The company focuses on various R&D models, including independent research, technology transfer, and collaborative research, particularly in controlled-release technology and antibody drugs[34]. - The company is actively developing innovative drugs based on EDB single-chain antibody fusion proteins, which have demonstrated significant advantages in tumor targeting and long-lasting effects[44]. - Research and development expenses increased to ¥29,092,255.24 in the first half of 2021, compared to ¥18,819,798.00 in the same period of 2020, marking a rise of 54.3%[143]. Market and Product Development - The company operates over 60 retail chain pharmacies in Hefei and surrounding areas, expanding its retail business through acquisitions, adding 21 new stores during the reporting period[38]. - The company has a strong logistics distribution capability in Anhui province, enhancing its pharmaceutical wholesale and distribution business[33]. - The company’s main industrial products target cardiovascular, digestive, and dermatological conditions, contributing to its diversified product portfolio[28]. - The company has successfully launched the first and only nifedipine osmotic pump preparation in China, which has shown continuous growth in sales since its market introduction[45]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[165]. Governance and Compliance - The company has established a multi-tier governance structure, including a board of directors and various specialized committees[178]. - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[98]. - The company has not faced any penalties or rectification requirements during the reporting period, indicating compliance with regulations[100]. - The half-year financial report was not audited, which may affect the perception of financial reliability[95]. Environmental Responsibility - The company has established a comprehensive environmental monitoring plan, conducting regular checks on wastewater, waste gas, and noise levels to ensure compliance with environmental regulations[84]. - The company faced an administrative penalty of 100,000 RMB for violating water pollution prevention laws, but it did not significantly impact production operations[85]. - The company emphasizes clean production audits to promote energy conservation and pollution reduction at the source[82]. - The company has developed emergency response plans for environmental incidents, ensuring preparedness for potential environmental risks[83].

Financial Performance - The company's operating revenue for the first quarter of 2021 was CNY 549,093,775.22, representing a 21.34% increase compared to CNY 452,514,094.49 in the same period last year[9]. - The net profit attributable to shareholders of the listed company reached CNY 41,691,278.46, a 43.59% increase from CNY 29,035,673.38 year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 40,065,652.84, marking a significant increase of 65.10% from CNY 24,267,266.02 in the previous year[9]. - The basic earnings per share for the first quarter was CNY 0.45, up 7.14% from CNY 0.42 in the same period last year[9]. - Total operating revenue for Q1 2021 was CNY 549,093,775.22, an increase of 21.4% compared to CNY 452,514,094.49 in Q1 2020[42]. - Net profit for Q1 2021 reached CNY 41,691,278.46, representing a 43.7% increase from CNY 29,035,673.38 in Q1 2020[44]. - The company reported a gross profit of CNY 215,832,650.89 for Q1 2021, reflecting a gross margin of approximately 39.2%[42]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,659,458,754.63, an increase of 8.04% from CNY 1,536,019,607.62 at the end of the previous year[9]. - The total liabilities as of March 31, 2021, were CNY 443,774,345.14, up from CNY 362,026,476.59 at the end of 2020, marking an increase of about 22.6%[36]. - The company's non-current assets totaled CNY 294,994,007.23, an increase from CNY 244,058,157.18, reflecting a growth of about 20.9%[35]. - The total equity increased to CNY 1,078,265,973.01 as of March 31, 2021, compared to CNY 1,039,920,682.68 at the end of 2020[41]. - The total current assets amounted to CNY 1,364,464,747.40, an increase from CNY 1,291,961,450.44 as of December 31, 2020, reflecting a growth of approximately 5.6%[34]. Cash Flow - The net cash flow from operating activities was CNY 7,347,550.03, a decrease of 56.91% compared to CNY 17,053,489.84 in the same period last year[9]. - Cash and cash equivalents decreased by 77.89% to ¥169,517,172.34 due to cash management activities[16]. - The cash flow from investment activities showed a net outflow of ¥594,926,964.59, significantly higher than the outflow of ¥10,090,168.99 in the previous period[53]. - The cash and cash equivalents at the end of the period were ¥125,564,084.28, down from ¥170,585,405.59 in the previous period, a decrease of about 26.4%[54]. Expenses - Total operating costs for Q1 2021 were CNY 500,968,799.74, up 19.7% from CNY 418,504,423.71 in the same period last year[42]. - Research and development expenses surged by 183.84% to ¥12,404,825.37, reflecting increased payments based on project progress[17]. - Financial expenses rose by 90.87% to -¥877,953.59, mainly due to increased interest income from deposits[18]. Other Financial Metrics - The company reported a government subsidy of CNY 608,718.15, which is closely related to its business operations[9]. - The company reported no overdue receivables or non-compliance with external guarantees during the reporting period, indicating a stable financial position[28]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period, ensuring financial integrity[29]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[42].

Financial Performance - The company's operating revenue for 2020 was ¥1,894,291,431.49, representing a 14.80% increase compared to ¥1,650,031,851.68 in 2019[18]. - The net profit attributable to shareholders for 2020 was ¥135,116,122.69, a 28.51% increase from ¥105,141,106.21 in 2019[18]. - The net profit after deducting non-recurring gains and losses was ¥117,875,523.70, up 26.35% from ¥93,296,390.02 in 2019[18]. - The company's total assets at the end of 2020 reached ¥1,536,019,607.62, a 72.62% increase from ¥889,813,094.50 at the end of 2019[18]. - The net assets attributable to shareholders increased by 98.98% to ¥1,173,993,131.03 from ¥589,997,699.73 in 2019[18]. - The basic earnings per share for 2020 was ¥1.94, reflecting a 28.48% increase from ¥1.51 in 2019[18]. - The company generated a net cash flow from operating activities of ¥172,489,276.44, which is a 15.53% increase compared to ¥149,299,646.81 in 2019[18]. Dividend Distribution - The company reported a profit distribution plan based on a base of 92,640,000 shares, proposing a cash dividend of 5 RMB per 10 shares (including tax) with no bonus shares[4]. - The cash dividend total for the past three years has been consistently increasing, with 20.84 million CNY in 2018, 27.79 million CNY in 2019, and 46.32 million CNY in 2020[121]. Corporate Governance - The company has established a comprehensive corporate governance structure to protect the rights of shareholders and creditors[161]. - The company has committed to minimizing related party transactions and ensuring fair pricing in any necessary transactions[128]. - The company will ensure that no related party transactions harm the legitimate rights and interests of the company and its shareholders[128]. - The company has emphasized the importance of independent directors in ensuring the fairness of related party transaction pricing[127]. Research and Development - The company has established a permeation pump controlled-release technology platform, enhancing its product development and industrialization capabilities[26]. - The company is focusing on innovative drug development and high-end formulations to enhance its competitive advantage in the market[38]. - The company has multiple ongoing research projects, including the development of controlled-release formulations such as 盐酸曲美他嗪 and 硝苯地平[54]. - The company invested in R&D, resulting in the approval of 5 invention patents and 4 utility model patents during the reporting period[56]. - The company has established a comprehensive R&D team and collaborates with academic institutions to enhance its research capabilities and maintain its competitive edge in the pharmaceutical industry[44]. Market Position and Strategy - The company aims to become a regional leader in pharmaceutical commerce by improving logistics efficiency and reducing costs through modernized distribution channels[42]. - The company is actively expanding its product pipeline in the ophthalmic medication sector through acquisitions, commissioned research, and collaborative development to meet market demands[46]. - The company is exploring various R&D models, including independent research, technology transfer, and collaborative research[29]. - The company is focused on establishing a comprehensive pharmaceutical industry chain, emphasizing high-end formulation R&D and production[95]. Risks and Challenges - The company faces risks related to the reliance on core products and the potential failure of key products to pass consistency evaluations, which could adversely affect future operations[113]. - The company acknowledges the risks associated with new product development, including long R&D cycles and potential delays due to technical difficulties or policy changes[114]. - The company recognizes the risks associated with talent shortages and the potential loss of core technical personnel, which could impact its operational capabilities[110]. Environmental and Social Responsibility - The company actively participates in social welfare activities, including donations of cash and medical supplies during the COVID-19 pandemic, contributing to local communities and healthcare institutions[166]. - The company has established a series of environmental protection measures and emergency procedures to ensure compliance with environmental standards in all production processes[172]. - The company has made donations of cash and supplies to support flood relief efforts, demonstrating its commitment to community support[166]. Shareholder Information - The company completed its initial public offering (IPO) of 23.16 million shares, increasing total shares from 69.48 million to 92.64 million[185]. - The largest shareholder, Ji Junqiu, holds 27.58% of the shares, totaling 25,548,600 shares[191]. - The company has a share lock-up period of 12 months from the date of its IPO, during which shareholders cannot transfer or manage their shares[125]. - The company has committed to not transferring or managing shares for 36 months post-IPO, ensuring stability in shareholding during this period[124].